On July 13, 2023 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, reported that Marc Hedrick, M.D., President and Chief Executive Officer, will give two presentations at the Targeted Radiopharmaceuticals Summit taking place July 25-27, 2023 in Boston, Massachusetts (Press release, PLUS THERAPEUTICS, JUL 13, 2023, View Source [SID1234633230]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentations will describe data from the ReSPECT-GBM clinical study evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM), as well as provide an overview of the Company’s scientific approach, current pipeline and a snapshot of where it is headed.

Details of presentations:

Title Re-186 Radiolabelled NanoLiposomes for Rare Brain & Spinal Cord Tumors

Date July 26, 2023, 9:30 a.m. ET

Session Targeted Radiopharmaceuticals in the US: The Past, the Present & the Future



Title Novel Approaches to Central Nervous System Targeted Radiotherapeutics

Date July 26, 2023, 2:30 p.m. ET

Session Addressing TRP Toxicity: Chelators, Clearance & Drug Design

A copy of the presentations will be made available under the Presentations tab of the Investors section of the Company’s website following the meeting at View Source